RTW Biotech Opportunities Ltd (LSE: RTWG), a London-listed investment fund focused on the biopharmaceutical and medical technology sectors, has announced the repurchase of 497,014 ordinary shares at a price of $2.47 per share on 16 November 2026. The bought-back shares will be transferred to treasury, reducing the company's total voting rights to 317,296,634. The transaction was conducted under authority granted by shareholders at the company's Annual General Meeting in June 2026, which permits repurchases of up to 14.99% of issued ordinary shares.
Key Points
- RTW Biotech Opportunities Ltd (RTWG) is an LSE-listed investment fund managed by RTW Investments, LP
- The company repurchased 497,014 ordinary shares at $2.47 per share on 16 November 2026
- Total voting rights now stand at 317,296,634 following settlement; 28,670,806 shares are held in treasury
- Investors should watch whether further buybacks follow ahead of the 2027 AGM authority renewal
Treasury Placement Leaves 317,296,634 Voting Rights After 28.6 Million Shares Held Back
Following settlement of the latest transaction, RTW Biotech Opportunities Ltd's total issued ordinary share capital stands at 345,967,440 shares. Of these, 28,670,806 are now held in treasury and carry no voting rights, leaving 317,296,634 shares with active voting entitlements. The announcement confirms that this denominator figure of 317,296,634 is the reference shareholders should use when calculating whether they are required to disclose interests or changes to interests under the FCA's Disclosure and Transparency Rules. No premium to net asset value may be paid under the terms of the buyback programme.
June 2026 AGM Authority Permits Repurchase of Up to 14.99% of RTW Biotech's Ordinary Shares
The buyback is being conducted under a mandate approved by RTW Biotech Opportunities Ltd shareholders at the Annual General Meeting held in June 2026. That authority permits the company to repurchase a maximum of 14.99% of its ordinary shares, and remains in force until a new authority is granted — expected at the 2027 AGM — or until it is expressly revoked. The announcement notes that the actual number of shares repurchased will depend on prevailing market conditions. Jefferies International Limited has been appointed as broker for the buyback transactions, in accordance with FCA Listing Rules.
RTW Investments, LP Manages the Fund's Focus on Next-Generation Therapies and Medical Technologies
RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, described in the announcement as a healthcare-focused entrepreneurial investment firm with deep scientific expertise. The fund targets transformative assets with high growth potential across the biopharmaceutical and medical technology sectors, with an emphasis on companies developing next-generation therapies and technologies. The investment strategy is long-term in orientation, aiming to support innovative businesses developing life-changing treatments. As an investment fund rather than a direct operating company, its performance is closely tied to the valuations and progress of its underlying portfolio holdings.




Please wait processing your request...